Tavros Therapeutics utilizes functional and computational genomics to identify genetic vulnerabilities in tumors, enabling the discovery of novel therapeutic targets and biomarkers for precision cancer treatment. The company addresses the challenge of high unmet clinical needs in oncology by developing targeted therapies that improve patient outcomes and reduce side effects.
Funding
$135M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers lack effective targeted therapies due to the complex and heterogeneous nature of tumors, leading to high unmet clinical needs and suboptimal patient outcomes. Identifying novel therapeutic targets and biomarkers remains a significant challenge in precision oncology.
Solution
Tavros Therapeutics employs functional and computational genomics to pinpoint genetic vulnerabilities specific to individual tumors, enabling the discovery of novel therapeutic targets and biomarkers. By analyzing the unique genetic makeup of tumors, Tavros identifies vulnerabilities that can be exploited with targeted therapies. This approach aims to improve patient outcomes by developing treatments that are more effective and have fewer side effects, ultimately advancing precision cancer treatment.
Target Audience
Tavros Therapeutics primarily targets oncology researchers, pharmaceutical companies, and clinical oncologists seeking to develop and implement precision cancer therapies.
Features
- Functional genomics platform for identifying genetic vulnerabilities in tumors.
- Computational genomics technologies to uncover novel therapeutic targets.
- Biomarker discovery for patient stratification and treatment selection.
- Identification of novel clinical positioning strategies for existing molecules.
- Strategic partnerships to validate platform and expand therapeutic potential.